FDA approves first ethnically targeted drug

Share this article:
The FDA yesterday gave a green light to the first drug targeted to a specific ethnic group when the agency approved NitroMed's BiDil to treat heart failure in African-American patients. 
The agency called the approval "a step toward the promise of personalized medicine."
FDA associate director of medical policy Robert Temple said in a statement that the approval "is a striking example of how a treatment can benefit some patients even if it does not help all patients."
As reported at www.mmm-online.com, an FDA advisory panel recommended that the agency approve the drug last week.
The push to market the BiDil has raised questions about how marketing, regulatory and political considerations play a role in new drug development, with critics of NitroMed saying the company has managed the system and patent law, along with historical inequities, to drive its product to market.
NitroMed, said its decision to test and market the drug now is backed by a study of 1,050 African-American heart failure patients that showed BiDil significantly reduced death and hospitalization.
Analysts expect that potential annual domestic sales of BiDil could reach $825 million based on the 750,000 African-American heart failure patients in the U.S.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.